Works matching DE "THERAPEUTIC use of monoclonal antibodies"
Results: 5000
Prospects for Targeting PD-1 and PD-L1 in Various Tumor Types.
- Published in:
- Oncology (08909091), 2014, p. 1
- By:
- Publication type:
- Article
Pertuzumab: Increasing the Options.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 3, p. 199
- By:
- Publication type:
- Article
Neoadjuvant Pertuzumab: the Exception That Proves the Rule?
- Published in:
- Oncology (08909091), 2014, v. 28, n. 3, p. 197
- By:
- Publication type:
- Article
Pertuzumab and Its Accelerated Approval: Evolving Treatment Paradigms and New Challenges in the Management of HER2-Positive Breast Cancer.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 3, p. 186
- By:
- Publication type:
- Article
Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 2, p. 110
- By:
- Publication type:
- Article
Personalized Medicine and Anti-EGFR Antibody Therapy in the Treatment of Metastatic Colorectal Cancer: KRAS and Beyond.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 2, p. 96
- By:
- Publication type:
- Article
Cancer Metabolism as a Therapeutic Target: Metabolic Synthetic Lethality.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 5, p. 1
- By:
- Publication type:
- Article
Advances in the Systemic Treatment of Metastatic Melanoma.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 5, p. 1
- By:
- Publication type:
- Article
HER2-Directed Therapy for Metastatic Breast Cancer.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 3, p. 166
- By:
- Publication type:
- Article
Fifteen Years of Anti-HER2 Therapy.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 3, p. 151
- By:
- Publication type:
- Article
Targeted Therapy: Its Status and Promise in Selected Solid Tumors Part I: Areas of Major Impact.
- Published in:
- Oncology (08909091), 2012, v. 26, n. 10, p. 936
- By:
- Publication type:
- Article
ALL in Adults: How Can We Do Better?
- Published in:
- Oncology (08909091), 2012, v. 26, n. 9, p. 864
- By:
- Publication type:
- Article
Treatment of Adult Acute Lymphoblastic Leukemia (ALL) With a Focus on Emerging Investigational and Targeted Therapies.
- Published in:
- 2012
- By:
- Publication type:
- Case Study
Treatment of Adult ALL: More Questions Than Answers.
- Published in:
- Oncology (08909091), 2012, v. 26, n. 9, p. 865
- By:
- Publication type:
- Article
ASCO REPORTS: HIGHLIGHTS FROM EXCLUSIVE ONCOLOGY INTERVIEWS.
- Published in:
- 2012
- Publication type:
- Interview
Sequencing of Therapies in Advanced Prostate Cancer.
- Published in:
- Oncology (08909091), 2012, v. 26, n. 1, p. 82
- By:
- Publication type:
- Article
Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches.
- Published in:
- Oncology (08909091), 2012, v. 26, n. 1, p. 70
- By:
- Publication type:
- Article
What Is the Current Standard of Care for Anti-HER2 Neoadjuvant Therapy in Breast Cancer?
- Published in:
- Oncology (08909091), 2012, v. 26, n. 1, p. 20
- By:
- Publication type:
- Article
Light-Induced, Specific Killing of Cancer Cells.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 14, p. 1416
- Publication type:
- Article
Dramatic CLEOPATRA Findings Support Addition of Pertuzumab to Regimen for HER2-Positive Metastatic Breast Cancer.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 14, p. 1416
- Publication type:
- Article
Evolution of Treatment Options for Patients With CRPC and Bone Metastases: Bone-Targeted Agents That Go Beyond Palliation of Symptoms to Improve Overall Survival.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 14, p. 1362
- By:
- Publication type:
- Article
FDA Approves Brentuximab Vedotin for Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 10, p. 904
- Publication type:
- Article
The IGF-1R Pathway as a Therapeutic Target.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 6, p. 538
- By:
- Publication type:
- Article
A Renaissance in the Medical Treatment of Advanced Prostate Cancer.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 14, p. 1308
- By:
- Publication type:
- Article
CTLA-4-Blocking Immunotherapy With Ipilimumab for Advanced Melanoma.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 14, p. 1302
- By:
- Publication type:
- Article
Ipilimumab for Advanced Melanoma: Let's Not Throw Caution to the Winds.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 14, p. 1296
- By:
- Publication type:
- Article
Ipilimumab: A Promising Immunotherapy for Melanoma.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 14, p. 1280
- By:
- Publication type:
- Article
Improving the Therapeutic Benefits of Ipilimumab.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 14, p. 1288
- By:
- Publication type:
- Article
Future Directions - of Monoclonal Antibody Use in Personalized Lung Cancer Therapy.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 13, p. 1226
- By:
- Publication type:
- Article
Unanswered Questions: Monoclonal Antibodies in the Treatment of Advanced Non-Small- Cell Lung Cancer.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 13, p. 1216
- By:
- Publication type:
- Article
Bevacizumab in Advanced Lung Cancer: In Search of the Right Drug for the Right Patient.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 13, p. 1223
- By:
- Publication type:
- Article
FDA and Avastin: Crossroads in an Era of Targeted Therapies.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 11, p. 989
- By:
- Publication type:
- Article
Diagnosing and Treating Chronic Lymphocytic Leukemia in 2009.
- Published in:
- Oncology (08909091), 2009, v. 23, n. 12, p. 1030
- By:
- Publication type:
- Article
Neoadjuvant pembro shows benefit in MIBC.
- Published in:
- Urology Times, 2021, v. 49, n. 10, p. 7
- By:
- Publication type:
- Article
Olaparib/pembrolizumab, focal therapy, and ultrasonic propulsion of stones: AUA 2021 highlights.
- Published in:
- 2021
- By:
- Publication type:
- Proceeding
EV-301 investigator discusses enfortumab vedotin: "Significant survival advantage" vs chemotherapy was observed.
- Published in:
- 2021
- By:
- Publication type:
- Interview
Pembrolizumab/axitinib RCC survival bene?t is sustained in long-term results: Median OS was 45.7 months with the combination vs 40.1 months with sunitinib.
- Published in:
- Urology Times, 2021, v. 49, n. 7, p. 17
- By:
- Publication type:
- Article
UroPipeline.
- Published in:
- Urology Times, 2021, v. 49, n. 7, p. 8
- By:
- Publication type:
- Article
Pivotal data published for sacituzumab govitecan for bladder cancer.
- Published in:
- Urology Times, 2021, v. 49, n. 6, p. 41
- By:
- Publication type:
- Article
NCCN adds lenvatinib/pembrolizumab to Category 1 recommendation.
- Published in:
- Urology Times, 2021, v. 49, n. 5, p. 34
- By:
- Publication type:
- Article
Part B data reveal increased usage of denosumab and mitomycin: Leuprolide acetate remains the most commonly used androgen suppression drug.
- Published in:
- Urology Times, 2021, v. 49, n. 4, p. 37
- By:
- Publication type:
- Article
Gomella discusses the state of the treatment paradigm for NMIBC: BCG remains the standard of care, but excitement is growing for new treatments.
- Published in:
- 2021
- By:
- Publication type:
- Proceeding
UroPipeline.
- Published in:
- Urology Times, 2021, v. 49, n. 4, p. 7
- By:
- Publication type:
- Article
First-line pembrolizumab/axitinib sustains survival benefit in kidney cancer.
- Published in:
- Urology Times, 2020, v. 48, n. 12, p. 34
- By:
- Publication type:
- Article
Expert provides update on treatments for BCG-unresponsive NMIBC: Pembrolizumab and nadofaragene firadenovec show promise in non--muscle-invasive bladder cancer.
- Published in:
- Urology Times, 2020, v. 48, n. 12, p. 28
- By:
- Publication type:
- Article
Urology in 2020. PARP inhibitors make clinical splash as COVID-19's impact is felt throughout specialty.
- Published in:
- Urology Times, 2020, v. 48, n. 12, p. 1
- By:
- Publication type:
- Article
UPDATES ON DRUGS, DEVICES, AND TESTS.
- Published in:
- Urology Times, 2020, v. 48, n. 11, p. 8
- By:
- Publication type:
- Article
Cabozantinib combo induces clinical activity in advanced ccRCC.
- Published in:
- Urology Times, 2020, v. 48, n. 10, p. 41
- By:
- Publication type:
- Article
UroPipeline.
- Published in:
- Urology Times, 2020, v. 48, n. 9, p. 19
- By:
- Publication type:
- Article
Novel PSMA-targeted radioligand therapy shows promise in mCRPC.
- Published in:
- Urology Times, 2020, v. 48, n. 8, p. 21
- By:
- Publication type:
- Article